Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 181

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 6
Chunk 181
---
 objectives of our general compensation plans and other employee benefit plans as well as our general compensation plans and other employee benefit plans in light of such...  

  retaining and approving the compensation of any compensation advisors;  

  reviewing all equity-compensation plans to be submitted for shareholder approval under the NASDAQ listing rules, and reviewing and approving all equity-compensation plans that are exempt from s...  

  evaluating the appropriate level of compensation for board and board committee service by non-employee directors; and  

  reviewing and approving description of executive compensation included in our annual report on Form 20-F.  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────

Nominating and Corporate Governance Committee

Douglas Arner and Justin Wu
currently serve on the nominating and corporate governance committee, which is chaired by Professor Arner. Our Board of Directors has
determined that each member of the nominating and corporate governance committee is “independent” as that term is defined
in the applicable rules of the NASDAQ Capital Market. The nominating and corporate governance committee’s responsibilities include:

  assisting our Board of Directors in identifying prospective director nominees and recommending nominees for election by the shareholders or appointment by our Board of Directors;  

  advising the board of directors periodically with respect to significant developments in the law and practice of corporate governance as well as our compliance with applicable laws and regulati...  

  overseeing the evaluation of our Board of Directors; and  

  recommending members for each board committee of our Board of Directors.  

Scientific Advisory Boards

We restructured the Scientific
Assessment Committee into a newly formed Scientific Advisory Board. The Scientific Advisory Board shall help the Company sharpen its focus
on innovation and technological advancements and address critical scientific challenges in our research and development; it will provide
overall advise on the scientific development of the company. As of the date of this annual report, we have
29 memberson this board.

In light of the Company’s
focus on developing treatment for infectious diseases, we have established a second scientific advisory board, i. e., the Infectious Diseases
Scientific Advisory Board in April 2020. As of the date hereof, the Infectious Diseases Scientific AdvisoryBoard
has 4 members.

Family Relationships

There is no family relationship
among any of our directors or executive officers.

Duties of Directors

Under Cayman Islands law,
our directors have a duty to act honestly, in good faith and bona fide with a view to our best interests. Our directors also have